Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

1.4K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.4K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

995
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
995
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

909
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
909
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

1.3K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.3K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

989
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
989

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Response to Comment on Sakaki et al. Quantitative β-Cell Mass Imaging Redefines Disease Staging and Glycemic Control in Type 1 Diabetes.

Diabetes·2026
Same author

Monogenic diabetes in Japan and India: A call for broader screening.

Diabetes research and clinical practice·2026
Same author

Activating Transcription Factor 6α Governs Stress-Adaptive Pancreatic β-Cell Mass Expansion by Coordinating Proliferation and Survival.

Diabetes·2026
Same author

[<sup>18</sup>F]FB(ePEG12)12-Exendin-4 positron emission tomography/magnetic resonance imaging for precise preoperative localization of a pancreatic-head insulinoma: a case report with review of literature.

Endocrine journal·2026
Same author

Quantitative β-Cell Mass Imaging Redefines Disease Staging and Glycemic Control in Type 1 Diabetes.

Diabetes·2026
Same author

Seasonal variation in fresh fruit consumption: insights from the Sukoyaka health survey 2019-2020 in Japan.

BMC nutrition·2026

Related Experiment Video

Updated: Apr 15, 2026

Screening for Thermotoga maritima Membrane-Bound Pyrophosphatase Inhibitors
09:11

Screening for Thermotoga maritima Membrane-Bound Pyrophosphatase Inhibitors

Published on: November 23, 2019

7.3K

[DPP-4 inhibitor].

Shin-Ichi Harashima, Nobuya Inagaki

    Nihon Rinsho. Japanese Journal of Clinical Medicine
    |March 28, 2015
    PubMed
    Summary
    This summary is machine-generated.

    Dipeptidyl peptidase-4 (DPP-4) inhibitors effectively manage type 2 diabetes in Japan, showing similar glycemic control across agents. These drugs offer flexible treatment options, including combination therapy with insulin or sulfonylurea.

    More Related Videos

    Homogeneous Time-resolved F&#246;rster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
    07:30

    Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

    Published on: May 10, 2018

    9.9K
    Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog
    08:37

    Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

    Published on: November 5, 2014

    10.4K

    Related Experiment Videos

    Last Updated: Apr 15, 2026

    Screening for Thermotoga maritima Membrane-Bound Pyrophosphatase Inhibitors
    09:11

    Screening for Thermotoga maritima Membrane-Bound Pyrophosphatase Inhibitors

    Published on: November 23, 2019

    7.3K
    Homogeneous Time-resolved F&#246;rster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
    07:30

    Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

    Published on: May 10, 2018

    9.9K
    Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog
    08:37

    Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

    Published on: November 5, 2014

    10.4K

    Area of Science:

    • Endocrinology
    • Pharmacology
    • Metabolic Diseases

    Background:

    • Seven dipeptidyl peptidase-4 (DPP-4) inhibitors are available in Japan.
    • These agents are suitable for various stages of type 2 diabetes, provided insulin secretion capacity is preserved.

    Purpose of the Study:

    • To summarize the efficacy of DPP-4 inhibitors on glycemic control.
    • To present an algorithm for DPP-4 inhibitor treatment in Japanese patients with type 2 diabetes.

    Main Methods:

    • Review of existing data on DPP-4 inhibitor efficacy.
    • Analysis of treatment algorithms and patient populations in Japan.

    Main Results:

    • Monotherapy with DPP-4 inhibitors decreases HbA1c levels by 0.6-1.0%.
    • DPP-4 inhibitors demonstrate greater efficacy in the Japanese population compared to Western populations.
    • Basal insulin therapy can be switched to combination therapy with DPP-4 inhibitors and sulfonylurea in select Japanese patients.

    Conclusions:

    • DPP-4 inhibitors are effective and versatile treatment options for type 2 diabetes in Japan.
    • Treatment algorithms should consider patient-specific factors, including insulin secretion capacity and population-specific efficacy.